DelveInsight's 'Bipolar Disorder Pipeline Insight 2025' report provides comprehensive global coverage of pipeline therapies for bipolar disorder across various stages of clinical development. The ...
Dublin, July 21, 2025 (GLOBE NEWSWIRE) -- The "Bipolar Disorder Market - A Global and Regional Analysis: Focus on Class Type and Country Analysis - Analysis and Forecast, 2025-2035" report has been ...
(RTTNews) - LB Pharmaceuticals Inc. (LBRX), a clinical-stage biopharmaceutical company, announced the initiation of a Phase 2 trial of investigational drug LB-102 in bipolar depression, dubbed ...
Xenon Pharmaceuticals on Thursday said it has temporarily paused enrolling new patients in clinical studies testing its experimental drug for major depression and bipolar disorder, following reports ...
While anecdotal evidence and some case studies suggest cannabis may benefit those with bipolar disorder, studies have reported mixed results. The endocannabinoid system is thought to play a role in ...
March 5 (Reuters) - Memory Pharmaceuticals Corp. said its experimental drug for treating acute mania in bipolar disorder proved ineffective in a mid-stage trial. However, the company will go ahead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results